Double‐blind, randomised, placebo‐controlled crossover trial to evaluate the clinical efficacy of rifaximin in patients with moderate to severe active Crohn’s disease

GastroHep ◽  
2020 ◽  
Vol 2 (5) ◽  
pp. 185-192 ◽  
Author(s):  
Scott D. Lee ◽  
Anand Singla ◽  
Stephen J. Rulyak ◽  
Kindra Clark‐Snustad
Sign in / Sign up

Export Citation Format

Share Document